Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Das Thema chronische Unterbauch- und Viszeralschmerzen wird im Live-Webinar am 7. Mai von 17.30 bis 19 Uhr aus internistischer, gynäkologischer und psychologisch-neurowissenschaftlicher Perspektive beleuchtet. Besprochen werden krankheitsbedingte Ursachen, Mechanismen der kognitiven Schmerzmodulation sowie mögliche Therapieoptionen. Die Fortbildung ist mit 2 CME-Punkten zertifiziert. Melden Sie sich jetzt an!
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 1/2012

01.02.2012 | Kidney Diseases (G Ciancio, Section Editor)

Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year

verfasst von: Marine Gross-Goupil, Christophe Massard, Alain Ravaud

Erschienen in: Current Urology Reports | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

During the past half-decade, clinical trials have permitted major progress in treatment of metastatic renal cell carcinoma with the first generation of targeted therapies (bevacizumab, sunitinib, sorafenib, everolimus, and temsirolimus). New targeted agents such as axitinib, tivozanib, and dovitinib, all of which are tyrosine kinase inhibitors, have been developed in treatment of metastatic renal cell carcinoma. In the same time, more information regarding mechanism of disease and drug resistance shed light on new targets and new potent agents. We report an overview of the more relevant data published over the past year, which may modify the therapeutic landscape of kidney cancer in the near future.
Literatur
1.
• Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and tomorrow. Oncologist. 2011;16(2):45–50. This article is a review of the treatment of kidney cancer in 2011. PubMedCrossRef
2.
Motzer RJ. New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview. Oncologist. 2011;16(2):1–3.PubMedCrossRef
3.
•• Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061–8. This article reports the efficacy of a new tyrosine kinase inhibitor in a first-line setting of mRCC. PubMedCrossRef
4.
Motzer RJ, Hutson TE, Olsen MR, et al. Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: renal EFFECT Trial. J Clin Oncol. 2011;29(suppl: LBA 308).
5.
•• Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist. 2011;16(suppl2):32–44. The author addresses the importance of prevention and treatment of adverse events of the targeted therapies to ensure efficacy. PubMedCrossRef
6.
Furge KA, MacKeigan JP, Teh BT. Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol. 2010;11(6):571–8.PubMedCrossRef
7.
Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463(7279):360–3.PubMedCrossRef
8.
•• Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469(7331):539–42. This article emphasizes that PBRM1 gene may be a major molecular abnormality on renal carcinoma. PubMedCrossRef
9.
• Suwaki N, Vanhecke E, Atkins KM, et al. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med. 2011;3(85):85ra47. The authors report new potent targeted agents. PubMedCrossRef
10.
Hammers HJ, Verheul HM, Salumbides B, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther. 2010;9(6):1525–35.PubMedCrossRef
11.
Cho TP, Dong SY, Jun F, et al. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives. J Med Chem. 2010;53(22):8140–9.PubMedCrossRef
12.
Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res. 2010;16(13):3507–16.PubMedCrossRef
13.
Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75.PubMedCrossRef
14.
Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer: a phase II study. Lancet Oncol. 2007;8:975–84.PubMedCrossRef
15.
•• Rini B. Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial. J Clin Oncol. 2011;29 (suppl; abstr 4503). This article reports the superiority of axitinib compared to sorafenib in the second-line setting.
16.
Bhargava P, Esteves B, Al-Adhami M, et al. Activity of tivozanib (AV-951) in patients with renal cell carcinoma (RCC): subgroup analysis from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2010;28:15s(suppl: abstr 4599).
17.
Motzer RJ, Bhargava P, Esteves B, et al. A phase III, randomized, controlled study to compare tivozanib with sorafenib in patients (pts) with advanced renal cell carcinoma (RCC). J Clin Oncol. 2011;29(suppl 7; abstr 310).
18.
Angevin E, Lopez JA, Pande A, et al. TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: a phase I/II dose finding and biomarker study. J Clin Oncol. 2009;15s (suppl; abstr 3563).
19.
• Angevin E, Grünwald V, Ravaud A, et al. A phase II study of dovitinib (TKI258), an FGFR-and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC). J Clin Oncol. 2011;29(suppl; abstr 4551). This abstract reports the safety and promising efficacy of a new tyrosine kinase inhibitor in patients previously treated with VEGF inhibitors and/or mTOR Inhibitors.
20.
21.
Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358:966–70.PubMedCrossRef
22.
Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon-alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655–9.PubMedCrossRef
23.
Logan T, McDermott D, Dutcher J, et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. J Clin Oncol. 2008;26(suppl; abstr 5050).
24.
Patard JJ, Pignot G, Escudier B, et al. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 2011;60(4):684–90.PubMedCrossRef
25.
Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185(1):60–6.PubMedCrossRef
26.
Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794–9.PubMedCrossRef
27.
Richey SL, Culp SH, Jonasch E, et al. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. 2011;22(5):1048–53.PubMedCrossRef
28.
Powles T, Kayani I, Blank C, et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol. 2011;22:1041–7.PubMedCrossRef
29.
•• Chapin BF, Delacroix SC, Culp SH, et al. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol. 2011;60(5):964–71. This article suggests that surgery still remains safe after exposure to targeted therapy. PubMedCrossRef
30.
Escudier B. Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol. 2011;22:995–6.PubMedCrossRef
31.
32.
33.
Russo P. Multi-modal treatment for metastatic renal cancer: the role of surgery. World J Urol. 2010;28:295–301.PubMedCrossRef
34.
• Karam JA, Rini B, Varella L, et al. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol. 2011;185:439–44. This article underlines the importance of considering surgery even in the metastatic setting. PubMedCrossRef
35.
Bex A, Jonasch E, Kirkali Z, et al. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol. 2010;58:819–28.PubMedCrossRef
36.
Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6(6):327–38.PubMedCrossRef
37.
38.
Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007;110:543–50.PubMedCrossRef
39.
•• Manola J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res. 2011;17(16):5443–50. The authors report a new prognostic model in the era of targeted therapy. PubMedCrossRef
40.
• Schmidinger M, Vogl UM, Bojic M, et al. Hypothyroidism in patients with renal cell carcinoma. Blessing or curse? Cancer. 2011;117:534–44. This article concludes that biologic hypothyroidism during treatment with sunitinib or sorafenib may be a predictive factor of response and a prognostic factor. PubMedCrossRef
41.
Rini B, Cohen DP, Lu DR, et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Canc Inst. 2011;103:763–73.CrossRef
42.
• Maitland ML, Bakris GL, Black HR, et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signalling pathway inhibitors. J Natl Cancer Inst. 2010;102(9):596–604. The authors report the prognostic role of hypertension (systolic or diastolic) during VEGF-R–inhibitor treatment. CrossRef
43.
Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist. 2011;16 suppl 2:14–22.PubMedCrossRef
44.
45.
Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20(9):2376–81.PubMedCrossRef
Metadaten
Titel
Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year
verfasst von
Marine Gross-Goupil
Christophe Massard
Alain Ravaud
Publikationsdatum
01.02.2012
Verlag
Current Science Inc.
Erschienen in
Current Urology Reports / Ausgabe 1/2012
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-011-0232-y

Weitere Artikel der Ausgabe 1/2012

Current Urology Reports 1/2012 Zur Ausgabe

New Techniques: Imaging (A Atala, Section Editor)

Update on Thermal Ablation of Renal Cell Carcinoma: Oncologic Control, Technique Comparison, Renal Function Preservation, and New Modalities

Kidney Diseases (G Ciancio, Section Editor)

Evaluation and Management of Small Renal Masses: Looking Beyond the Tumor Margin

New Techniques: Imaging (A Atala, Section Editor)

Evaluation of Treatment Response in Patients with Metastatic Renal Cell Carcinoma: Role of State-of-the-Art Cross-Sectional Imaging

New Techniques: Imaging (A Atala, Section Editor)

Advanced Renal Mass Imaging: Diffusion and Perfusion MRI

Kidney Diseases (G Ciancio, Section Editor)

Current Status of Robot-Assisted Partial Nephrectomy

Kidney Diseases (G Ciancio, Section Editor)

Update on Surgical Management of Renal Cell Carcinoma with Venous Extension

Neu im Fachgebiet Urologie

Männern mit Zystitis Schmalband-Antibiotika verordnen

03.05.2024 Zystitis Nachrichten

Die akute Zystitis von Männern und ihre Therapie sind wenig erforscht. Norwegische Forscher haben das nachgeholt. Ihr Rat: Erst einmal keine Breitbandantibiotika verordnen.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

D-Mannose ohne Nutzen in der Prävention von HWI-Rezidiven

02.05.2024 Harnwegsinfektionen in der Urologie Nachrichten

D-Mannose, eine Hoffnungsträgerin in der Rezidivprophylaxe von Harnwegsinfektionen, hat in einer Studie nicht mehr bewirken können als ein Placebo. Die Empfehlung zur Einnahme entfalle damit, so die Autoren.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise